Report International

03/25/2026

Collaboration remains one of the most powerful tools in ending TB. By bringing together data, expertise, and resources across diverse global settings, networks like RePORT International are accelerating innovation and turning ideas into action.

03/25/2026

Addressing TB before it progresses to active disease is critical to reducing transmission. Expanding access to affordable latent TB diagnostics and simplifying treatment regimens can significantly improve adherence and patient outcomes.

03/24/2026

Real impact will come from closing persistent gaps in TB care, particularly in vaccines, diagnostics, and treatment. Shorter, more effective regimens and stronger political commitment are essential to translating scientific advances into meaningful outcomes worldwide.

03/24/2026

Progress depends on using today’s tools to their fullest potential while continuing to invest in what comes next. Expanding preventive therapy, strengthening active case finding, and advancing new diagnostics and vaccines will define the next phase of TB control.

03/23/2026

The fight against TB is no longer limited by science. We have the tools to diagnose earlier, treat more effectively, and target high burden areas with precision. The priority now is scaling these solutions through sustained, country led investment and accountability.

03/23/2026

On the eve of World TB Day, we are happy to share the RePORT International March Newsletter. Click here to accesshttps://reportinternational.org/wp-content/uploads/2026/03/RePORT-March-2026-Newsletter.pdf

03/23/2026

World TB Day marks a moment to reflect on both progress and possibility. Across the RePORT International network, leaders are focused on how emerging tools from earlier detection to more precise risk identification can be deployed to interrupt transmission and improve long term outcomes.

03/02/2026

Congratulations to our colleagues in on their recent publication in JCI Insight, which provides additional insight into immunity and progression to active tuberculosis disease. Advancing our understanding of host immune responses remains central to improving prediction, prevention, and treatment strategies for TB.

🔗 Read the article: https://insight.jci.org/articles/view/202134

03/01/2026

Join us in congratulating Dr Rajita Bhavaraju on her Lifetime Achievement Award! Click on link to read more!

https://reportinternational.org/celebrating-dr-rajita-r-bhavaraju/

02/27/2026

Childhood tuberculosis remains underdiagnosed and is frequently under- or overtreatment compared to adult TB. The Shortened Regimen for Drug-Susceptible TB in Children (SMILE-TB) trial, led by the SMART4TB Consortium and funded by the U.S. government, is evaluating a shorter treatment regimen for children with pulmonary and lymph node TB. This work addresses a critical gap in pediatric TB care and aims to improve treatment tolerability and outcomes.

🔗 Learn more:https://tbcenter.jhu.edu/wp-content/uploads/2025/12/SMILE-TB-Study.pdf

02/25/2026

The Atlas of TB Innovations aims to serve as a centralized, evolving reference for scientific, technological, and operational advancements in tuberculosis. By cataloguing innovations as they progress from development through implementation and regulatory review, the Atlas seeks to provide transparency on effectiveness, reliability, and global uptake.

🔗 Explore the Atlas: https://www.atlasoftbinnovations.in/

Welcome to India Innovation Summit - Pioneering solutions to End TB

02/23/2026

New TB vaccines will require more than scientific advancement; they will depend on trusted community engagement and equitable implementation. "What Could Go Right: Vital Partnerships with Communities and Civil Society for New Tuberculosis Vaccines," developed with community partners and supported by Wellcome, examines how civil society organizations help build the “infrastructures of trust” necessary for vaccine acceptance, demand, and access.

🔗 Learn more: https://www.treatmentactiongroup.org/publication/what-could-go-right-vital-partnerships-for-new-tuberculosis-vaccines/

What Could Go Right: Vital Partnerships with Communities and Civil Society for New Tuberculosis Vaccines, written together with community partners and supported by Wellcome, explores the indispensable role of communities and civil society in preparing the way for new TB vaccines and ensuring their s...